{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-006501","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-08-17T10:04:44+00:00","discovered_at":"2026-08-17T10:10:01.646122+00:00","generated_at":"2026-08-17T10:10:20.128824+00:00","sec_items":["1.01","3.02","8.01","5.02","5.07","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Valion Bio terminates CEO, appoints COO, secures $1.5M funding from 3i","bullets":["CEO Michael K. Handley terminated effective Aug 16, 2026; Lisa Wolf appointed COO, remains CFO.","Letter Agreement with 3i, LP: $1.5M for 1,500 Series B Preferred at $1,000/share plus warrants.","Second closing of $1.5M for another 1,500 shares if definitive side letter executed by Aug 24, 2026.","Royalty Agreement: 5% of Velocity Bioworks gross revenue for 10 years to 3i and other purchasers.","Stockholders approved reverse stock split (1:5 to 1:50) at special meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-006501","json":"https://secwatch.observer/filing/0001683168-26-006501.json","markdown":"https://secwatch.observer/filing/0001683168-26-006501.md","text":"https://secwatch.observer/filing/0001683168-26-006501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826006501/0001683168-26-006501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826006501/valion_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-17T10:10:20.128824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}